ETON Share Price Performance
US$23.24
10.22 (78.49%)
25.0% undervalued intrinsic discount
US$31.00
Fair Value
Price US$23.24
AnalystLowTarget US$31.00
AnalystHighTarget US$35.00
AnalystConsensusTarget US$29.79
Fair ValueUS$31.00
Share Pricen/a
Eton Pharmaceuticals, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 33 Fair Values set on narratives written by author
ETON Community Narratives
AN
Fair Value US$31 25.0% undervalued intrinsic discount
Orphan Drug Reliance Will Confront Regulatory Hurdles Yet Regain Traction
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$35 33.6% undervalued intrinsic discount
Aging Population And Improved Diagnosis Will Unlock Orphan Drug Markets
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$30 22.5% undervalued intrinsic discount
Advances In Diagnosis And Orphan Drugs Will Open New Horizons
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
Orphan Drug Reliance Will Confront Regulatory Hurdles Yet Regain Traction
Key Takeaways Heightened regulatory scrutiny and policy reforms could limit revenue growth and put pressure on Eton's drug pricing and profitability. Dependence on a small product portfolio and external licensing may expose Eton to competition risks and constrain future innovation and earnings stability.Read more
11
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$31
25.0% undervalued intrinsic discount
Fair Value
Profit Margin
32.32%
Future PE
16.27x
Price in 2029
US$36.98
Aging Population And Improved Diagnosis Will Unlock Orphan Drug Markets
Key Takeaways Expansion of patient access and label indications could rapidly accelerate growth and significantly boost both revenue and operating margins beyond current expectations. Eton's proven execution in specialty acquisitions and favorable industry trends uniquely position it for sustained outsized demand and above-trend earnings growth.Read more
17
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$35
33.6% undervalued intrinsic discount
Fair Value
Profit Margin
32.07%
Future PE
19.18x
Price in 2028
US$41.2
Advances In Diagnosis And Orphan Drugs Will Open New Horizons
Key Takeaways Expansion in ultra-rare disease therapies, new product launches, and regulatory incentives strengthen growth prospects and improve margins. Investments in patient support, education, and targeted distribution drive higher adoption, recurring revenues, and faster scaling of profitability.Read more
51
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
US$30
22.5% undervalued intrinsic discount
Fair Value
Profit Margin
32.34%
Future PE
19.49x
Price in 2028
US$35.31
Trending Discussion
Recently Updated Narratives
AN
ETON: Upcoming Product Launches And New Guidance Will Reshape Earnings Profile
Fair Value: US$31 25.0% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Population And Improved Diagnosis Will Unlock Orphan Drug Markets
Fair Value: US$35 33.6% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Advances In Diagnosis And Orphan Drugs Will Open New Horizons
Fair Value: US$30 22.5% undervalued intrinsic discount
11 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Eton Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.17
- 59.83%
- -5.75%
- 116.8%
About ETON
- Founded
- 2017
- Employees
- 44
- CEO
- WebsiteView website
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
